# A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

> **NCT04517253** · PHASE2,PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 10 (actual)

## Conditions studied

- Nakajo-Nishimura Syndrome
- Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome
- STING-Associated Vasculopathy With Onset in Infancy
- Aicardi Goutieres Syndrome

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT04517253
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-27
- **Primary completion:** 2023-04-04
- **Final completion:** 2024-11-28
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study was terminated due to efficacy/effectiveness reasons
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04517253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04517253, "A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04517253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*